Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 40Other hematologic neoplasm 36Dermatologic 29Lymphoid 24Gastrointestinal 23Myeloid 20Plasma cell 17Thoracic 6Sarcoma 4Other solid neoplasm 3Gynecologic 3CNS 3Breast 3Other neoplasm 2Head & Neck 2Endocrine 2NET 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interferon-alpha × Endocrine × Clear all
NCT02838342 2021-08-02

EPICentro

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed
28 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT00178698 2011-03-03

FR-WB-TT/che

The University of Texas Health Science Center, Houston

Phase 2 Unknown
36 enrolled
EndocrineGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡